ICU Medical, Inc. (NASDAQ:ICUI) was more active in the last trading session as around 0.28 million shares exchanged hands on Wall Street, representing an increase from its normal capacity of 0.14 million shares. A -2.97% change after the initial price of $174, sent the closing price to $166.65.

ICU Medical, Inc. (ICUI) Analyst Opinion

ICU Medical, Inc. has a consensus outperform rating from 5 Wall Street analysts, and the number of shares currently sold short amount to at least 5.99% of shares outstanding. The stock sank -2.69% last month and is up 13.1 this year. Wall Street is only getting more bullish on the stock, with 2 of analysts who cover ICUI having a buy-equivalent rating. Analysts have placed a $176.75 price target on ICU Medical, Inc., suggesting a 6.06% gain from recent close. It’s currently trading about -5.58% below its 52-week high.

ICU Medical, Inc. Earnings Surprise

ICU Medical, Inc. (ICUI) failed to surprise the stock market in its last reported earnings when it earned $0.76 a piece versus the consensus-estimated $0.77. Its revenue totaled $318.3 million up 28.48% from the previous quarter.

ICU Medical, Inc. (NASDAQ:ICUI) Intraday View

This stock (ICUI) is ahead of its 52-week low with 38.71%. Its last month’s stock price volatility remained 2.52% which for the week stands at 2.03%. The share price has moved backward from its 20 days moving average, trading at a distance of -3.43% and stays -2.48% away from its 50 days moving average. Over the last five days, shares have faced -4.31% losses and now is up 8.2% since hitting its 200-day moving average of $158.49. ICU Medical, Inc. (ICUI) has made its way to a 12-month gain of 32.46%.

Turning to ABIOMED, Inc. (NASDAQ:ABMD), its shares were trading at $150.01 a retreat of $-5.84, on the trading floor. The stock, after opening at $155.35, touched a high of $156.2 before paring much of its gains. So far, analysts are sticking with their bullish recommendations with the consensus call at 1.4. ABIOMED, Inc. has 6 buy ratings, 1 holds and 0 sells even after the stock tumbled -4.7% from its high of $157.41 to a $6.48 billion market value through last close.

ABIOMED, Inc. (ABMD) Consensus Price Target

The company’s consensus rating on Reuter’s scale remained unchanged from 1.44 to 1.44 during a month. Analysts set a 12-month price target of $162.75 a share. The target implies a 8.49% spike from where the shares are currently trading. Also, the current price highlights a discount of 19.99% to analysts’ high consensus price target.

ABIOMED, Inc. (NASDAQ:ABMD) Intraday Trading

The counter witnessed a trading volume of 0.38 million shares versus an average volume of 0.31 million shares during last trading session. Its last month’s stock price volatility remained 2.42% which for the week approaches 2.06%. The lowest price the stock reached in the last trading day was $149.94 and compares with the $95.14 52-week low. The stock recovered 57.68% since its low point and has performed 33.13% year-to-date.

Previous articleAnalysts Give These Stocks Mix Nod: Banco Bilbao Vizcaya Argentaria, S.A. (BBVA), BioMarin Pharmaceutical Inc. (BMRN)
Next articleMajor Analyst Actions Under Review: GrubHub Inc. (GRUB), GoPro, Inc. (GPRO)